drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00831 | DB11986 | 1,178 | 484 | [
"DDInter1866",
"DDInter648"
] | Trifluoperazine | Entrectinib | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1178,
24,
484
]
],
[
[
1178,
23,
112
],
[
112,
23,
484
]
],
[
[
1178,
24,
222
],
[
222,
23,
484
]
],
[
[
1178,
24,
774
],
[
774,
... | [
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Trifluoperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
... | Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Sibutram... |
DB06228 | DB15233 | 792 | 1,650 | [
"DDInter1609",
"DDInter142"
] | Rivaroxaban | Avapritinib | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
792,
25,
1650
]
],
[
[
792,
24,
1478
],
[
1478,
24,
1650
]
],
[
[
792,
63,
1101
],
[
1101,
24,
1650
]
],
[
[
792,
24,
908
],
[
908,
... | [
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacafto... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexar... |
DB00026 | DB00041 | 1,184 | 1,648 | [
"DDInter94",
"DDInter38"
] | Anakinra | Aldesleukin | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Moderate | 1 | [
[
[
1184,
24,
1648
]
],
[
[
1184,
24,
322
],
[
322,
63,
1648
]
],
[
[
1184,
63,
305
],
[
305,
24,
1648
]
],
[
[
1184,
25,
1624
],
[
1624,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia... |
DB00549 | DB04868 | 522 | 478 | [
"DDInter1955",
"DDInter1293"
] | Zafirlukast | Nilotinib | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
522,
24,
478
]
],
[
[
522,
24,
1468
],
[
1468,
63,
478
]
],
[
[
522,
6,
6017
],
[
6017,
45,
478
]
],
[
[
522,
21,
28762
],
[
28762,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Zafirlukast (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Zafirlukast (Compoun... |
DB00800 | DB01143 | 572 | 923 | [
"DDInter720",
"DDInter65"
] | Fenoldopam | Amifostine | A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation. | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | Moderate | 1 | [
[
[
572,
24,
923
]
],
[
[
572,
21,
29425
],
[
29425,
60,
923
]
],
[
[
572,
24,
714
],
[
714,
24,
923
]
],
[
[
572,
63,
1214
],
[
1214,
... | [
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Fenoldopam",
"{u} (Compound) causes {v} (Side Effect)",
"Myocardial ischaemia"
],
[
"Myocardial ischaemia",
"{u}... | Fenoldopam (Compound) causes Myocardial ischaemia (Side Effect) and Myocardial ischaemia (Side Effect) is caused by Amifostine (Compound)
Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when ... |
DB01238 | DB09291 | 673 | 741 | [
"DDInter118",
"DDInter1615"
] | Aripiprazole | Rolapitant | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
673,
24,
741
]
],
[
[
673,
63,
506
],
[
506,
24,
741
]
],
[
[
673,
24,
159
],
[
159,
63,
741
]
],
[
[
673,
24,
1342
],
[
1342,
2... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
]... | Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Larot... |
DB00816 | DB11124 | 1,674 | 209 | [
"DDInter1346",
"DDInter1560"
] | Orciprenaline | Racepinephrine | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Racepinephrine is a racemic mixture consisting of d- and l- enantiomers. Epinephrine is a non-selective α- and β-adrenergic receptor agonist. It is a bronchodilator used in the temporary relief of mild symptoms of intermittent asthma including wheezing, tightness of chest and shortness of breath. It is an active ingred... | Moderate | 1 | [
[
[
1674,
24,
209
]
],
[
[
1674,
23,
1042
],
[
1042,
23,
209
]
],
[
[
1674,
62,
1573
],
[
1573,
23,
209
]
],
[
[
1674,
24,
688
],
[
688,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Racepinephrine"
]
],
[
[
"Orciprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
... | Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Tetracosactide and Tetracosactide may cause a minor interaction that can limit clinical effects when taken with Racepinephrine
Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Prednison... |
DB00197 | DB00381 | 1,324 | 376 | [
"DDInter1881",
"DDInter79"
] | Troglitazone | Amlodipine | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Moderate | 1 | [
[
[
1324,
24,
376
]
],
[
[
1324,
24,
409
],
[
409,
1,
376
]
],
[
[
1324,
24,
1081
],
[
1081,
40,
376
]
],
[
[
1324,
24,
466
],
[
466,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amlodipine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine (Compound) resembles Amlodipine (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) resembles Amlodipine (Comp... |
DB00398 | DB08912 | 79 | 1,040 | [
"DDInter1702",
"DDInter462"
] | Sorafenib | Dabrafenib | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
79,
24,
1040
]
],
[
[
79,
6,
3834
],
[
3834,
45,
1040
]
],
[
[
79,
7,
13388
],
[
13388,
46,
1040
]
],
[
[
79,
34,
6732
],
[
6732,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"BRAF"
],
[
"BRAF",
"{u} (Gene) is bound by {v} (Compound)",
... | Sorafenib (Compound) binds BRAF (Gene) and BRAF (Gene) is bound by Dabrafenib (Compound)
Sorafenib (Compound) upregulates PSAT1 (Gene) and PSAT1 (Gene) is upregulated by Dabrafenib (Compound)
Sorafenib (Compound) binds MAP2K5 (Gene) and Sorafenib (Compound) upregulates MAP2K5 (Gene) and MAP2K5 (Gene) is upregulated by ... |
DB00627 | DB01261 | 265 | 170 | [
"DDInter1286",
"DDInter1679"
] | Niacin | Sitagliptin | Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565] | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
265,
24,
170
]
],
[
[
265,
21,
28921
],
[
28921,
60,
170
]
],
[
[
265,
24,
52
],
[
52,
62,
170
]
],
[
[
265,
63,
1179
],
[
1179,
... | [
[
[
"Niacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Niacin",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {... | Niacin (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sitagliptin (Compound)
Niacin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Sitagliptin
Ni... |
DB00647 | DB01124 | 675 | 1,411 | [
"DDInter528",
"DDInter1828"
] | Dextropropoxyphene | Tolbutamide | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
675,
24,
1411
]
],
[
[
675,
24,
959
],
[
959,
40,
1411
]
],
[
[
675,
63,
245
],
[
245,
40,
1411
]
],
[
[
675,
6,
3486
],
[
3486,
... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"... | Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbu... |
DB00682 | DB01563 | 126 | 680 | [
"DDInter1951",
"DDInter349"
] | Warfarin | Chloral hydrate | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | A hypnotic and sedative used in the treatment of insomnia. The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments. It is no longer considered useful as an anti-anxiety medication. | Moderate | 1 | [
[
[
126,
24,
680
]
],
[
[
126,
24,
593
],
[
593,
24,
680
]
],
[
[
126,
1,
1376
],
[
1376,
24,
680
]
],
[
[
126,
24,
593
],
[
593,
63... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloral hydrate"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate
Warfarin (Compound) resembles Diphenhydramine (Compound) and Diphenhydramine may cause a moderate interaction t... |
DB06372 | DB12001 | 259 | 564 | [
"DDInter1594",
"DDInter7"
] | Rilonacept | Abemaciclib | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
259,
24,
564
]
],
[
[
259,
24,
748
],
[
748,
24,
564
]
],
[
[
259,
63,
58
],
[
58,
24,
564
]
],
[
[
259,
24,
151
],
[
151,
63,
... | [
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
],
... | Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine and Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Alefacept ... |
DB01344 | DB11255 | 1,231 | 1,371 | [
"DDInter1830",
"DDInter374"
] | Tolevamer | Chromium picolinate | Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, H... | Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. It is a coordination complex consisting of chromium(III) and picolinic acid. Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. Chromium ions are show... | Moderate | 1 | [
[
[
1231,
24,
1371
]
],
[
[
1231,
63,
660
],
[
660,
62,
245
],
[
245,
24,
1371
]
],
[
[
1231,
63,
708
],
[
708,
63,
245
],
[
245,
24,
... | [
[
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],... | Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picol... |
DB00658 | DB09100 | 965 | 320 | [
"DDInter1663",
"DDInter1799"
] | Sevelamer | Thyroid, porcine | Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel. | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyro... | Moderate | 1 | [
[
[
965,
24,
320
]
],
[
[
965,
21,
28787
],
[
28787,
60,
1144
],
[
1144,
24,
320
]
],
[
[
965,
21,
28722
],
[
28722,
60,
467
],
[
467,
2... | [
[
[
"Sevelamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Sevelamer",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) i... | Sevelamer (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Sevelamer (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Si... |
DB00656 | DB00816 | 827 | 1,674 | [
"DDInter1851",
"DDInter1346"
] | Trazodone | Orciprenaline | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Moderate | 1 | [
[
[
827,
24,
1674
]
],
[
[
827,
21,
28921
],
[
28921,
60,
1674
]
],
[
[
827,
63,
618
],
[
618,
24,
1674
]
],
[
[
827,
24,
484
],
[
484,
... | [
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Trazodone",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is cau... | Trazodone (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Orciprenaline (Compound)
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Orciprenal... |
DB00328 | DB00761 | 831 | 1,621 | [
"DDInter921",
"DDInter1497"
] | Indomethacin | Potassium chloride | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Moderate | 1 | [
[
[
831,
24,
1621
]
],
[
[
831,
21,
28809
],
[
28809,
60,
1621
]
],
[
[
831,
24,
1512
],
[
1512,
24,
1621
]
],
[
[
831,
40,
1263
],
[
1263... | [
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium chloride"
]
],
[
[
"Indomethacin",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Eff... | Indomethacin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Potassium chloride (Compound)
Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00294 | DB06273 | 1,336 | 980 | [
"DDInter701",
"DDInter1824"
] | Etonogestrel | Tocilizumab | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
1336,
24,
980
]
],
[
[
1336,
63,
1031
],
[
1031,
24,
980
]
],
[
[
1336,
1,
873
],
[
873,
24,
980
]
],
[
[
1336,
24,
629
],
[
629,
... | [
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
... | Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Etonogestrel (Compound) resembles Norgestimate (Compound) and Norgestimate may cause a moderate interacti... |
DB00209 | DB00985 | 352 | 1,443 | [
"DDInter1886",
"DDInter562"
] | Trospium | Dimenhydrinate | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyl... | Moderate | 1 | [
[
[
352,
24,
1443
]
],
[
[
352,
40,
11286
],
[
11286,
1,
1443
]
],
[
[
352,
24,
1376
],
[
1376,
63,
1443
]
],
[
[
352,
35,
357
],
[
357,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimenhydrinate"
]
],
[
[
"Trospium",
"{u} (Compound) resembles {v} (Compound)",
"Diphenylpyraline"
],
[
"Diphenylpyraline",
"{u} (Compou... | Trospium (Compound) resembles Diphenylpyraline (Compound) and Diphenylpyraline (Compound) resembles Dimenhydrinate (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when ... |
DB04843 | DB09076 | 1,511 | 1,116 | [
"DDInter1149",
"DDInter1899"
] | Mepenzolate | Umeclidinium | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
1511,
24,
1116
]
],
[
[
1511,
24,
849
],
[
849,
24,
1116
]
],
[
[
1511,
63,
1300
],
[
1300,
24,
1116
]
],
[
[
1511,
24,
337
],
[
337,
... | [
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Haloperidol and H... |
DB00570 | DB01229 | 147 | 973 | [
"DDInter1936",
"DDInter1378"
] | Vinblastine | Paclitaxel (protein-bound) | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Moderate | 1 | [
[
[
147,
24,
973
]
],
[
[
147,
24,
310
],
[
310,
63,
973
]
],
[
[
147,
5,
11579
],
[
11579,
44,
973
]
],
[
[
147,
6,
8374
],
[
8374,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Vinbla... |
DB00903 | DB09082 | 1,680 | 659 | [
"DDInter686",
"DDInter1934"
] | Etacrynic acid | Vilanterol | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1680,
24,
659
]
],
[
[
1680,
24,
1220
],
[
1220,
23,
659
]
],
[
[
1680,
63,
891
],
[
891,
23,
659
]
],
[
[
1680,
24,
1296
],
[
1296,
... | [
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
... | Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Prednisol... |
DB01174 | DB08916 | 697 | 26 | [
"DDInter1442",
"DDInter32"
] | Phenobarbital | Afatinib | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal grow... | Moderate | 1 | [
[
[
697,
24,
26
]
],
[
[
697,
63,
883
],
[
883,
40,
26
]
],
[
[
697,
6,
4973
],
[
4973,
45,
26
]
],
[
[
697,
21,
28787
],
[
28787,
6... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[... | Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Afatinib (Compound)
Phenobarbital (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Afatinib (Compound)
Phenobarbital (Compound) causes Dermatitis (Side Effect) and Dermati... |
DB00762 | DB09280 | 613 | 1,604 | [
"DDInter973",
"DDInter1101"
] | Irinotecan | Lumacaftor | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
613,
25,
1604
]
],
[
[
613,
24,
292
],
[
292,
24,
1604
]
],
[
[
613,
63,
522
],
[
522,
24,
1604
]
],
[
[
613,
24,
1501
],
[
1501,
... | [
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
],
[
"Regorafen... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zaf... |
DB09104 | DB11853 | 286 | 230 | [
"DDInter1118",
"DDInter1577"
] | Magnesium hydroxide | Relugolix | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Moderate | 1 | [
[
[
286,
24,
230
]
],
[
[
286,
63,
129
],
[
129,
23,
230
]
],
[
[
286,
63,
1213
],
[
1213,
24,
230
]
],
[
[
286,
62,
355
],
[
355,
2... | [
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutami... | Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Da... |
DB00427 | DB00777 | 1,233 | 146 | [
"DDInter1879",
"DDInter1537"
] | Triprolidine | Propiomazine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Moderate | 1 | [
[
[
1233,
24,
146
]
],
[
[
1233,
63,
508
],
[
508,
1,
146
]
],
[
[
1233,
24,
401
],
[
401,
63,
146
]
],
[
[
1233,
24,
1178
],
[
1178,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction th... |
DB00603 | DB09118 | 303 | 1,580 | [
"DDInter1137",
"DDInter1711"
] | Medroxyprogesterone acetate | Stiripentol | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
303,
24,
1580
]
],
[
[
303,
24,
283
],
[
283,
63,
1580
]
],
[
[
303,
24,
473
],
[
473,
24,
1580
]
],
[
[
303,
63,
1324
],
[
1324,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases wh... |
DB00529 | DB01246 | 789 | 820 | [
"DDInter779",
"DDInter45"
] | Foscarnet | Alimemazine | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
789,
24,
820
]
],
[
[
789,
24,
401
],
[
401,
24,
820
]
],
[
[
789,
21,
28662
],
[
28662,
60,
820
]
],
[
[
789,
24,
286
],
[
286,
... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Foscarnet (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Alimemazine (Compound... |
DB00712 | DB01138 | 1,274 | 804 | [
"DDInter763",
"DDInter1726"
] | Flurbiprofen | Sulfinpyrazone | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Moderate | 1 | [
[
[
1274,
24,
804
]
],
[
[
1274,
24,
998
],
[
998,
1,
804
]
],
[
[
1274,
6,
9320
],
[
9320,
45,
804
]
],
[
[
1274,
18,
4930
],
[
4930,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound)
Flurbiprofen (Compound) binds ABCC4 (Gene) and ABCC4 (Gene) is bound by Sulfinpyrazone (Compound)
Flurbiprofen (Compound) downregulates DLD (Gene)... |
DB00046 | DB01299 | 1,179 | 698 | [
"DDInter940",
"DDInter1722"
] | Insulin lispro | Sulfadoxine | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections. | Moderate | 1 | [
[
[
1179,
24,
698
]
],
[
[
1179,
24,
1247
],
[
1247,
40,
698
]
],
[
[
1179,
24,
161
],
[
161,
1,
698
]
],
[
[
1179,
24,
1560
],
[
1560,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadoxine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfadoxine (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembl... |
DB00465 | DB00635 | 886 | 1,573 | [
"DDInter1010",
"DDInter1515"
] | Ketorolac | Prednisone | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
886,
24,
1573
]
],
[
[
886,
24,
175
],
[
175,
40,
1573
]
],
[
[
886,
63,
251
],
[
251,
1,
1573
]
],
[
[
886,
24,
167
],
[
167,
1... | [
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
... | Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone (... |
DB00358 | DB14881 | 1,010 | 180 | [
"DDInter1140",
"DDInter1329"
] | Mefloquine | Oliceridine | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1010,
24,
180
]
],
[
[
1010,
23,
112
],
[
112,
23,
180
]
],
[
[
1010,
24,
401
],
[
401,
24,
180
]
],
[
[
1010,
63,
618
],
[
618,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and P... |
DB09049 | DB14975 | 1,135 | 988 | [
"DDInter1261",
"DDInter1949"
] | Naloxegol | Voxelotor | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Major | 2 | [
[
[
1135,
25,
988
]
],
[
[
1135,
62,
578
],
[
578,
24,
988
]
],
[
[
1135,
23,
971
],
[
971,
24,
988
]
],
[
[
1135,
24,
214
],
[
214,
... | [
[
[
"Naloxegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Voxelotor"
]
],
[
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
... | Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib and Gilteritini... |
DB01263 | DB11113 | 859 | 657 | [
"DDInter1494",
"DDInter307"
] | Posaconazole | Castor oil | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
859,
24,
657
]
],
[
[
859,
25,
927
],
[
927,
63,
657
]
],
[
[
859,
25,
1491
],
[
1491,
24,
657
]
],
[
[
859,
63,
891
],
[
891,
2... | [
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encor... | Posaconazole may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Posaconazole may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moder... |
DB00631 | DB00749 | 372 | 59 | [
"DDInter405",
"DDInter699"
] | Clofarabine | Etodolac | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Moderate | 1 | [
[
[
372,
24,
59
]
],
[
[
372,
7,
7720
],
[
7720,
45,
59
]
],
[
[
372,
7,
3727
],
[
3727,
46,
59
]
],
[
[
372,
21,
29093
],
[
29093,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
]
],
[
[
"Clofarabine",
"{u} (Compound) upregulates {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (Compoun... | Clofarabine (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Etodolac (Compound)
Clofarabine (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Etodolac (Compound)
Clofarabine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Etodolac (Compound)
Clofarabine m... |
DB12095 | DB12130 | 179 | 1,017 | [
"DDInter1760",
"DDInter1094"
] | Telotristat ethyl | Lorlatinib | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Major | 2 | [
[
[
179,
25,
1017
]
],
[
[
179,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
179,
63,
175
],
[
175,
24,
1017
]
],
[
[
179,
24,
971
],
[
971,
... | [
[
[
"Telotristat ethyl",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Telotristat ethyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Telotristat ethyl may cause a moderate interaction that could exacerbate diseases when taken with Triamcino... |
DB00762 | DB01320 | 613 | 651 | [
"DDInter973",
"DDInter783"
] | Irinotecan | Fosphenytoin | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Major | 2 | [
[
[
613,
25,
651
]
],
[
[
613,
63,
307
],
[
307,
1,
651
]
],
[
[
613,
64,
362
],
[
362,
1,
651
]
],
[
[
613,
24,
998
],
[
998,
1,
... | [
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil (Compound) resembles Fosphenytoin (Compound)
Irinotecan may lead to a major life threatening interaction when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Irinotecan may ... |
DB00305 | DB01033 | 377 | 328 | [
"DDInter1232",
"DDInter1156"
] | Mitomycin | Mercaptopurine | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Moderate | 1 | [
[
[
377,
24,
328
]
],
[
[
377,
21,
28787
],
[
28787,
60,
328
]
],
[
[
377,
23,
1299
],
[
1299,
23,
328
]
],
[
[
377,
24,
663
],
[
663,
... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
]
],
[
[
"Mitomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is ... | Mitomycin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Mercaptopurine (Compound)
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with M... |
DB09079 | DB14730 | 1,496 | 1,412 | [
"DDInter1296",
"DDInter264"
] | Nintedanib | Calaspargase pegol | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1496,
24,
1412
]
],
[
[
1496,
63,
792
],
[
792,
24,
1412
]
],
[
[
1496,
24,
159
],
[
159,
24,
1412
]
],
[
[
1496,
64,
1220
],
[
1220,
... | [
[
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],... | Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectin... |
DB00374 | DB00812 | 1,061 | 998 | [
"DDInter1852",
"DDInter1451"
] | Treprostinil | Phenylbutazone | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Moderate | 1 | [
[
[
1061,
24,
998
]
],
[
[
1061,
24,
804
],
[
804,
40,
998
]
],
[
[
1061,
63,
362
],
[
362,
1,
998
]
],
[
[
1061,
6,
6017
],
[
6017,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Sulfinpyrazone and Sulfinpyrazone (Compound) resembles Phenylbutazone (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenylbu... |
DB00563 | DB11652 | 663 | 1,155 | [
"DDInter1174",
"DDInter1891"
] | Methotrexate | Tucatinib | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
663,
24,
1155
]
],
[
[
663,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
663,
24,
609
],
[
609,
24,
1155
]
],
[
[
663,
63,
522
],
[
522,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and C... |
DB00046 | DB01359 | 1,179 | 729 | [
"DDInter940",
"DDInter1417"
] | Insulin lispro | Penbutolol | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
1179,
24,
729
]
],
[
[
1179,
24,
461
],
[
461,
1,
729
]
],
[
[
1179,
24,
699
],
[
699,
40,
729
]
],
[
[
1179,
24,
542
],
[
542,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Insu... |
DB00486 | DB04861 | 1,614 | 1,592 | [
"DDInter1253",
"DDInter1271"
] | Nabilone | Nebivolol | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Moderate | 1 | [
[
[
1614,
24,
1592
]
],
[
[
1614,
21,
28762
],
[
28762,
60,
1592
]
],
[
[
1614,
24,
849
],
[
849,
63,
1592
]
],
[
[
1614,
24,
1376
],
[
13... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {... | Nabilone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nebivolol (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol
Nabi... |
DB00877 | DB00939 | 629 | 1,338 | [
"DDInter1678",
"DDInter1135"
] | Sirolimus | Meclofenamic acid | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Major | 2 | [
[
[
629,
25,
1338
]
],
[
[
629,
7,
8318
],
[
8318,
46,
1338
]
],
[
[
629,
21,
28900
],
[
28900,
60,
1338
]
],
[
[
629,
63,
752
],
[
752,
... | [
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Sirolimus",
"{u} (Compound) upregulates {v} (Gene)",
"DMTF1"
],
[
"DMTF1",
"{u} (Gene) is upregulated by {v} (Compound)",... | Sirolimus (Compound) upregulates DMTF1 (Gene) and DMTF1 (Gene) is upregulated by Meclofenamic acid (Compound)
Sirolimus (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Meclofenamic acid (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when... |
DB00927 | DB12141 | 1,559 | 971 | [
"DDInter712",
"DDInter817"
] | Famotidine | Gilteritinib | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1559,
24,
971
]
],
[
[
1559,
23,
1247
],
[
1247,
23,
971
]
],
[
[
1559,
62,
112
],
[
112,
23,
971
]
],
[
[
1559,
63,
485
],
[
485,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Famotidine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Famotidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole... |
DB00963 | DB12364 | 1,263 | 1,421 | [
"DDInter241",
"DDInter200"
] | Bromfenac | Betrixaban | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
1263,
25,
1421
]
],
[
[
1263,
63,
305
],
[
305,
24,
1421
]
],
[
[
1263,
24,
222
],
[
222,
24,
1421
]
],
[
[
1263,
24,
714
],
[
714,
... | [
[
[
"Bromfenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
... | Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Bromfenac may cause a moderate interaction that could exacerbate diseases w... |
DB00323 | DB00486 | 1,062 | 1,614 | [
"DDInter1829",
"DDInter1253"
] | Tolcapone | Nabilone | Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
1062,
24,
1614
]
],
[
[
1062,
24,
530
],
[
530,
1,
1614
]
],
[
[
1062,
21,
28789
],
[
28789,
60,
1614
]
],
[
[
1062,
24,
999
],
[
999,... | [
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
... | Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Tolcapone (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Nabilone (Compound)
Tolcapone may cause a mode... |
DB01033 | DB01206 | 328 | 37 | [
"DDInter1156",
"DDInter1086"
] | Mercaptopurine | Lomustine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | An alkylating agent of value against both hematologic malignancies and solid tumors. | Moderate | 1 | [
[
[
328,
24,
37
]
],
[
[
328,
5,
11555
],
[
11555,
44,
37
]
],
[
[
328,
21,
28722
],
[
28722,
60,
37
]
],
[
[
328,
62,
1176
],
[
1176,
... | [
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Mercaptopurine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} ... | Mercaptopurine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Lomustine (Compound)
Mercaptopurine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lomustine (Compound)
Mercaptopurine may cause a minor interaction that can limit clinical effects ... |
DB00332 | DB06691 | 1,089 | 849 | [
"DDInter970",
"DDInter1155"
] | Ipratropium | Mepyramine | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1089,
24,
849
]
],
[
[
1089,
24,
1594
],
[
1594,
24,
849
]
],
[
[
1089,
6,
12523
],
[
12523,
45,
849
]
],
[
[
1089,
24,
1116
],
[
1116... | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Ipratropium (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Ipratropium may ... |
DB00747 | DB11732 | 1,442 | 1,097 | [
"DDInter1647",
"DDInter1027"
] | Scopolamine | Lasmiditan | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
1442,
24,
1097
]
],
[
[
1442,
63,
701
],
[
701,
24,
1097
]
],
[
[
1442,
24,
662
],
[
662,
24,
1097
]
],
[
[
1442,
74,
85
],
[
85,
... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
... | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and C... |
DB00852 | DB06262 | 1,445 | 1,354 | [
"DDInter1545",
"DDInter606"
] | Pseudoephedrine | Droxidopa | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a def... | Moderate | 1 | [
[
[
1445,
24,
1354
]
],
[
[
1445,
24,
1191
],
[
1191,
40,
1354
]
],
[
[
1445,
24,
1148
],
[
1148,
24,
1354
]
],
[
[
1445,
1,
1357
],
[
135... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droxidopa"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
],
... | Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Levodopa and Levodopa (Compound) resembles Droxidopa (Compound)
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction t... |
DB08871 | DB14409 | 36 | 1,129 | [
"DDInter666",
"DDInter867"
] | Eribulin | Human adenovirus e serotype 4 strain cl-68578 antigen | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
36,
24,
1129
]
],
[
[
36,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
36,
63,
1683
],
[
1683,
24,
1129
]
],
[
[
36,
24,
1468
],
[
1468,
... | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eta... | Eribulin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Eribulin may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB11110 | DB14881 | 603 | 180 | [
"DDInter1115",
"DDInter1329"
] | Magnesium citrate | Oliceridine | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
603,
24,
180
]
],
[
[
603,
24,
124
],
[
124,
24,
180
]
],
[
[
603,
63,
618
],
[
618,
24,
180
]
],
[
[
603,
63,
702
],
[
702,
25,... | [
[
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
... | Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Abarelix... |
DB00204 | DB00757 | 228 | 1,166 | [
"DDInter580",
"DDInter581"
] | Dofetilide | Dolasetron | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Major | 2 | [
[
[
228,
25,
1166
]
],
[
[
228,
6,
8374
],
[
8374,
45,
1166
]
],
[
[
228,
21,
29081
],
[
29081,
60,
1166
]
],
[
[
228,
25,
752
],
[
752,
... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Dofetilide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dolaset... | Dofetilide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dolasetron (Compound)
Dofetilide (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Dolasetron (Compound)
Dofetilide may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may ca... |
DB00270 | DB01069 | 1,428 | 401 | [
"DDInter993",
"DDInter1533"
] | Isradipine | Promethazine | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1428,
24,
401
]
],
[
[
1428,
24,
820
],
[
820,
63,
401
]
],
[
[
1428,
24,
104
],
[
104,
24,
401
]
],
[
[
1428,
21,
28709
],
[
28709,
... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[... | Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and ... |
DB00963 | DB08816 | 1,263 | 578 | [
"DDInter241",
"DDInter1802"
] | Bromfenac | Ticagrelor | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
1263,
24,
578
]
],
[
[
1263,
21,
28645
],
[
28645,
60,
578
]
],
[
[
1263,
63,
1578
],
[
1578,
24,
578
]
],
[
[
1263,
76,
1172
],
[
117... | [
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Bromfenac",
"{u} (Compound) causes {v} (Side Effect)",
"Cough"
],
[
"Cough",
"{u} (Side Effect) is caused by {v} ... | Bromfenac (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Ticagrelor (Compound)
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Bromfena... |
DB01369 | DB09268 | 343 | 1,662 | [
"DDInter1558",
"DDInter1464"
] | Quinupristin | Picosulfuric acid | Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. The combination of... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
343,
24,
1662
]
],
[
[
343,
6,
8374
],
[
8374,
45,
251
],
[
251,
24,
1662
]
],
[
[
343,
6,
8374
],
[
8374,
45,
1482
],
[
1482,
23,
... | [
[
[
"Quinupristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Quinupristin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (... | Quinupristin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Quinupristin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Digitoxin (Compound) and Digito... |
DB00581 | DB01254 | 355 | 1,213 | [
"DDInter1018",
"DDInter484"
] | Lactulose | Dasatinib | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
355,
24,
1213
]
],
[
[
355,
21,
29180
],
[
29180,
60,
1213
]
],
[
[
355,
24,
1133
],
[
1133,
24,
1213
]
],
[
[
355,
63,
1555
],
[
1555... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Lactulose",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal distension"
],
[
"Abdominal distension",
"{u} (S... | Lactulose (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Dasatinib (Compound)
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases wh... |
DB00575 | DB01246 | 1,020 | 820 | [
"DDInter412",
"DDInter45"
] | Clonidine | Alimemazine | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1020,
24,
820
]
],
[
[
1020,
24,
104
],
[
104,
40,
820
]
],
[
[
1020,
24,
401
],
[
401,
24,
820
]
],
[
[
1020,
24,
649
],
[
649,
... | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction tha... |
DB04861 | DB08946 | 1,592 | 512 | [
"DDInter1271",
"DDInter962"
] | Nebivolol | Iopanoic acid | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Iopanoic acid contains iodine and is useful as a contrast medium in cholecystography. | Moderate | 1 | [
[
[
1592,
24,
512
]
],
[
[
1592,
24,
1106
],
[
1106,
24,
512
]
],
[
[
1592,
24,
777
],
[
777,
63,
512
]
],
[
[
1592,
63,
1648
],
[
1648,
... | [
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopanoic acid"
]
],
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadofosveset trisodium"
... | Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium and Gadofosveset trisodium may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00687 | DB01432 | 870 | 857 | [
"DDInter747",
"DDInter368"
] | Fludrocortisone | Cholestyramine | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water. | Moderate | 1 | [
[
[
870,
24,
857
]
],
[
[
870,
63,
1512
],
[
1512,
23,
857
]
],
[
[
870,
24,
1479
],
[
1479,
23,
857
]
],
[
[
870,
24,
1411
],
[
1411,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholestyramine"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Cholestyramine
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Acetylsal... |
DB08908 | DB09054 | 713 | 384 | [
"DDInter564",
"DDInter905"
] | Dimethyl fumarate | Idelalisib | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
713,
24,
384
]
],
[
[
713,
24,
1627
],
[
1627,
62,
384
]
],
[
[
713,
24,
725
],
[
725,
63,
384
]
],
[
[
713,
63,
328
],
[
328,
2... | [
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
... | Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Satrali... |
DB00804 | DB01235 | 1,507 | 1,191 | [
"DDInter543",
"DDInter1054"
] | Dicyclomine | Levodopa | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prev... | Moderate | 1 | [
[
[
1507,
24,
1191
]
],
[
[
1507,
21,
28786
],
[
28786,
60,
1191
]
],
[
[
1507,
24,
1264
],
[
1264,
23,
1191
]
],
[
[
1507,
24,
1376
],
[
... | [
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Dicyclomine",
"{u} (Compound) causes {v} (Side Effect)",
"Urinary retention"
],
[
"Urinary retention",
"{u} (Side... | Dicyclomine (Compound) causes Urinary retention (Side Effect) and Urinary retention (Side Effect) is caused by Levodopa (Compound)
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with... |
DB01268 | DB08880 | 1,151 | 1,510 | [
"DDInter1731",
"DDInter1771"
] | Sunitinib | Teriflunomide | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1151,
25,
1510
]
],
[
[
1151,
25,
129
],
[
129,
63,
1510
]
],
[
[
1151,
24,
1612
],
[
1612,
63,
1510
]
],
[
[
1151,
63,
1144
],
[
1144... | [
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"... | Sunitinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may... |
DB00366 | DB05541 | 1,594 | 801 | [
"DDInter600",
"DDInter239"
] | Doxylamine | Brivaracetam | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 . | Moderate | 1 | [
[
[
1594,
24,
801
]
],
[
[
1594,
63,
475
],
[
475,
24,
801
]
],
[
[
1594,
24,
999
],
[
999,
24,
801
]
],
[
[
1594,
74,
701
],
[
701,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brivaracetam"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Brivaracetam
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Th... |
DB00794 | DB01619 | 759 | 830 | [
"DDInter1521",
"DDInter1441"
] | Primidone | Phenindamine | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
759,
24,
830
]
],
[
[
759,
24,
537
],
[
537,
40,
830
]
],
[
[
759,
63,
1219
],
[
1219,
40,
830
]
],
[
[
759,
63,
13
],
[
13,
24,... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine (Compound) resembles Phenindamine (Compound)
Pr... |
DB00400 | DB06212 | 353 | 165 | [
"DDInter843",
"DDInter1833"
] | Griseofulvin | Tolvaptan | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Moderate | 1 | [
[
[
353,
24,
165
]
],
[
[
353,
6,
8374
],
[
8374,
45,
165
]
],
[
[
353,
21,
28681
],
[
28681,
60,
165
]
],
[
[
353,
24,
1135
],
[
1135,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Griseofulvin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Griseofulvin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tolvaptan (Compound)
Griseofulvin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Tolvaptan (Compound)
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with N... |
DB04575 | DB09045 | 35 | 52 | [
"DDInter1555",
"DDInter607"
] | Quinestrol | Dulaglutide | The 3-cyclopentyl ether of ethinyl estradiol. | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
35,
24,
52
]
],
[
[
35,
63,
170
],
[
170,
23,
52
]
],
[
[
35,
63,
609
],
[
609,
24,
52
]
],
[
[
35,
24,
1296
],
[
1296,
63,
... | [
[
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
... | Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and C... |
DB01138 | DB06441 | 804 | 936 | [
"DDInter1726",
"DDInter283"
] | Sulfinpyrazone | Cangrelor | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Major | 2 | [
[
[
804,
25,
936
]
],
[
[
804,
63,
848
],
[
848,
24,
936
]
],
[
[
804,
24,
885
],
[
885,
24,
936
]
],
[
[
804,
24,
738
],
[
738,
63,... | [
[
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibup... | Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and... |
DB00601 | DB00938 | 453 | 455 | [
"DDInter1073",
"DDInter1635"
] | Linezolid | Salmeterol | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
453,
24,
455
]
],
[
[
453,
24,
688
],
[
688,
63,
455
]
],
[
[
453,
7,
7669
],
[
7669,
46,
455
]
],
[
[
453,
21,
29024
],
[
29024,
... | [
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
... | Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Linezolid (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Salmeterol (Compound)
Linezolid ... |
DB00346 | DB00675 | 472 | 888 | [
"DDInter44",
"DDInter1744"
] | Alfuzosin | Tamoxifen | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
472,
24,
888
]
],
[
[
472,
24,
543
],
[
543,
63,
888
]
],
[
[
472,
24,
1376
],
[
1376,
64,
888
]
],
[
[
472,
6,
8374
],
[
8374,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
... | Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diph... |
DB00950 | DB08867 | 1,413 | 807 | [
"DDInter732",
"DDInter1897"
] | Fexofenadine | Ulipristal | Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamin... | Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocor... | Moderate | 1 | [
[
[
1413,
24,
807
]
],
[
[
1413,
62,
600
],
[
600,
23,
807
]
],
[
[
1413,
23,
609
],
[
609,
23,
807
]
],
[
[
1413,
24,
1017
],
[
1017,
... | [
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ulipristal"
]
],
[
[
"Fexofenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluconazole"
],
[... | Fexofenadine may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Fexofenadine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Cl... |
DB00039 | DB09074 | 1,253 | 1,362 | [
"DDInter1380",
"DDInter1327"
] | Palifermin | Olaparib | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1253,
24,
1362
]
],
[
[
1253,
24,
896
],
[
896,
24,
1362
]
],
[
[
1253,
63,
491
],
[
491,
24,
1362
]
],
[
[
1253,
24,
1619
],
[
1619,
... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and... |
DB00620 | DB00749 | 175 | 59 | [
"DDInter1855",
"DDInter699"
] | Triamcinolone | Etodolac | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Moderate | 1 | [
[
[
175,
24,
59
]
],
[
[
175,
6,
7720
],
[
7720,
45,
59
]
],
[
[
175,
21,
29187
],
[
29187,
60,
59
]
],
[
[
175,
63,
245
],
[
245,
2... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etodolac"
]
],
[
[
"Triamcinolone",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (Compound)... | Triamcinolone (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Etodolac (Compound)
Triamcinolone (Compound) causes Rhinitis (Side Effect) and Rhinitis (Side Effect) is caused by Etodolac (Compound)
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Gl... |
DB09330 | DB11853 | 985 | 230 | [
"DDInter1352",
"DDInter1577"
] | Osimertinib | Relugolix | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Major | 2 | [
[
[
985,
25,
230
]
],
[
[
985,
64,
129
],
[
129,
23,
230
]
],
[
[
985,
63,
1094
],
[
1094,
23,
230
]
],
[
[
985,
62,
112
],
[
112,
2... | [
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
]
],
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"... | Osimertinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may c... |
DB01170 | DB01222 | 1,150 | 617 | [
"DDInter846",
"DDInter246"
] | Guanethidine | Budesonide | An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem] | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
1150,
24,
617
]
],
[
[
1150,
63,
251
],
[
251,
1,
617
]
],
[
[
1150,
24,
1220
],
[
1220,
1,
617
]
],
[
[
1150,
6,
8374
],
[
8374,
... | [
[
[
"Guanethidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Guanethidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
... | Guanethidine may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Guanethidine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Budeso... |
DB01285 | DB10675 | 708 | 961 | [
"DDInter445",
"DDInter1065"
] | Corticotropin | Licorice | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Licorice allergenic extract is used in allergenic testing. | Moderate | 1 | [
[
[
708,
24,
961
]
],
[
[
708,
24,
1231
],
[
1231,
24,
961
]
],
[
[
708,
63,
1214
],
[
1214,
24,
961
]
],
[
[
708,
24,
1231
],
[
1231,
... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
],
[... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Licorice
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minox... |
DB00531 | DB06636 | 450 | 1,623 | [
"DDInter456",
"DDInter980"
] | Cyclophosphamide | Isavuconazonium | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
450,
24,
1623
]
],
[
[
450,
24,
1419
],
[
1419,
24,
1623
]
],
[
[
450,
24,
1593
],
[
1593,
63,
1623
]
],
[
[
450,
35,
1532
],
[
1532,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
... | Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Crizotin... |
DB01254 | DB01610 | 1,213 | 248 | [
"DDInter484",
"DDInter1912"
] | Dasatinib | Valganciclovir | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
1213,
24,
248
]
],
[
[
1213,
63,
563
],
[
563,
1,
248
]
],
[
[
1213,
21,
29209
],
[
29209,
60,
248
]
],
[
[
1213,
63,
1101
],
[
1101,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Dasatinib (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Valganciclovir (Compound)
Dasatinib may cause a moderate interac... |
DB00039 | DB08875 | 1,253 | 1,618 | [
"DDInter1380",
"DDInter262"
] | Palifermin | Cabozantinib | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
1253,
24,
1618
]
],
[
[
1253,
24,
1668
],
[
1668,
24,
1618
]
],
[
[
1253,
24,
800
],
[
800,
63,
1618
]
],
[
[
1253,
24,
322
],
[
322,
... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
],
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and D... |
DB00790 | DB01050 | 664 | 848 | [
"DDInter1431",
"DDInter900"
] | Perindopril | Ibuprofen | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
664,
24,
848
]
],
[
[
664,
24,
1053
],
[
1053,
1,
848
]
],
[
[
664,
6,
4973
],
[
4973,
45,
848
]
],
[
[
664,
21,
28773
],
[
28773,
... | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[... | Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine (Compound) resembles Ibuprofen (Compound)
Perindopril (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ibuprofen (Compound)
Perindopril (Compound) causes Urethral disorder (Side Effect) an... |
DB00468 | DB00501 | 1,424 | 752 | [
"DDInter1557",
"DDInter380"
] | Quinine | Cimetidine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Minor | 0 | [
[
[
1424,
23,
752
]
],
[
[
1424,
6,
21998
],
[
21998,
45,
752
]
],
[
[
1424,
21,
29062
],
[
29062,
60,
752
]
],
[
[
1424,
23,
112
],
[
112... | [
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound by {v} (C... | Quinine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Cimetidine (Compound)
Quinine (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Cimetidine (Compound)
Quinine may cause a minor interaction that can limit clinical effects when taken with Metronid... |
DB00902 | DB01115 | 104 | 336 | [
"DDInter1168",
"DDInter1291"
] | Methdilazine | Nifedipine | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Moderate | 1 | [
[
[
104,
24,
336
]
],
[
[
104,
63,
1428
],
[
1428,
1,
336
]
],
[
[
104,
63,
1081
],
[
1081,
40,
336
]
],
[
[
104,
24,
409
],
[
409,
... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
],
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Nifedipine (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) resembles Nifedipine (Comp... |
DB00277 | DB00863 | 1,031 | 1,194 | [
"DDInter1791",
"DDInter1568"
] | Theophylline | Ranitidine | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Moderate | 1 | [
[
[
1031,
24,
1194
]
],
[
[
1031,
24,
1127
],
[
1127,
1,
1194
]
],
[
[
1031,
6,
8374
],
[
8374,
45,
1194
]
],
[
[
1031,
21,
28658
],
[
286... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nizatidine"
],
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Nizatidine and Nizatidine (Compound) resembles Ranitidine (Compound)
Theophylline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ranitidine (Compound)
Theophylline (Compound) causes Vomiting (Side Effect) and Vomi... |
DB00843 | DB00889 | 479 | 1,133 | [
"DDInter583",
"DDInter840"
] | Donepezil | Granisetron | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
479,
24,
1133
]
],
[
[
479,
63,
19
],
[
19,
40,
1133
]
],
[
[
479,
63,
85
],
[
85,
1,
1133
]
],
[
[
479,
6,
8374
],
[
8374,
45,
... | [
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
... | Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine (Compound) resembles Granisetron (Compound)
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles Granisetron (Compound)
Do... |
DB00374 | DB09068 | 1,061 | 1,427 | [
"DDInter1852",
"DDInter1948"
] | Treprostinil | Vortioxetine | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
1061,
24,
1427
]
],
[
[
1061,
63,
25
],
[
25,
24,
1427
]
],
[
[
1061,
24,
256
],
[
256,
24,
1427
]
],
[
[
1061,
25,
802
],
[
802,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anistreplase"
],
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel a... |
DB09052 | DB10343 | 250 | 962 | [
"DDInter220",
"DDInter160"
] | Blinatumomab | Bacillus calmette-guerin substrain tice live antigen | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
250,
25,
962
]
],
[
[
250,
64,
1057
],
[
1057,
25,
962
]
],
[
[
250,
24,
270
],
[
270,
64,
962
]
],
[
[
250,
63,
663
],
[
663,
2... | [
[
[
"Blinatumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Blinatumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"... | Blinatumomab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Ocrel... |
DB00957 | DB01098 | 873 | 14 | [
"DDInter1314",
"DDInter1622"
] | Norgestimate | Rosuvastatin | Norgestimate was first described in the literature in 1977. It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat mod... | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Minor | 0 | [
[
[
873,
23,
14
]
],
[
[
873,
18,
1870
],
[
1870,
57,
14
]
],
[
[
873,
40,
1657
],
[
1657,
23,
14
]
],
[
[
873,
63,
305
],
[
305,
24... | [
[
[
"Norgestimate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Norgestimate",
"{u} (Compound) downregulates {v} (Gene)",
"MYC"
],
[
"MYC",
"{u} (Gene) is downregulated by {v... | Norgestimate (Compound) downregulates MYC (Gene) and MYC (Gene) is downregulated by Rosuvastatin (Compound)
Norgestimate (Compound) resembles Desogestrel (Compound) and Desogestrel may cause a minor interaction that can limit clinical effects when taken with Rosuvastatin
Norgestimate may cause a moderate interaction th... |
DB00539 | DB09078 | 11 | 1,228 | [
"DDInter1837",
"DDInter1036"
] | Toremifene | Lenvatinib | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Major | 2 | [
[
[
11,
25,
1228
]
],
[
[
11,
23,
112
],
[
112,
23,
1228
]
],
[
[
11,
25,
463
],
[
463,
23,
1228
]
],
[
[
11,
64,
1100
],
[
1100,
24... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Toremifene may lead to a major life threatening interaction when taken with Rifampicin and Rifampicin may caus... |
DB08827 | DB12267 | 990 | 1,476 | [
"DDInter1085",
"DDInter233"
] | Lomitapide | Brigatinib | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
990,
24,
1476
]
],
[
[
990,
23,
1135
],
[
1135,
23,
1476
]
],
[
[
990,
64,
168
],
[
168,
23,
1476
]
],
[
[
990,
63,
629
],
[
629,
... | [
[
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Lomitapide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Lomitapide may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Lomitapide may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a mino... |
DB01156 | DB14509 | 593 | 1,399 | [
"DDInter252",
"DDInter1081"
] | Bupropion | Lithium carbonate | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Major | 2 | [
[
[
593,
25,
1399
]
],
[
[
593,
63,
506
],
[
506,
24,
1399
]
],
[
[
593,
25,
820
],
[
820,
24,
1399
]
],
[
[
593,
64,
1010
],
[
1010,
... | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
... | Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Bupropion may lead to a major life threatening interaction when taken with Alimemazine and Ali... |
DB00572 | DB01246 | 85 | 820 | [
"DDInter136",
"DDInter45"
] | Atropine | Alimemazine | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
85,
24,
820
]
],
[
[
85,
24,
358
],
[
358,
24,
820
]
],
[
[
85,
24,
104
],
[
104,
40,
820
]
],
[
[
85,
24,
675
],
[
675,
25,
... | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
[
... | Atropine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Met... |
DB04845 | DB12130 | 309 | 1,017 | [
"DDInter1001",
"DDInter1094"
] | Ixabepilone | Lorlatinib | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
309,
24,
1017
]
],
[
[
309,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
309,
25,
976
],
[
976,
24,
1017
]
],
[
[
309,
63,
1554
],
[
1554,
... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Ixabepilone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may caus... |
DB00358 | DB12141 | 1,010 | 971 | [
"DDInter1140",
"DDInter817"
] | Mefloquine | Gilteritinib | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1010,
24,
971
]
],
[
[
1010,
23,
1247
],
[
1247,
23,
971
]
],
[
[
1010,
24,
485
],
[
485,
24,
971
]
],
[
[
1010,
24,
730
],
[
730,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Mefloquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine... |
DB00402 | DB00486 | 1,407 | 1,614 | [
"DDInter685",
"DDInter1253"
] | Eszopiclone | Nabilone | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
1407,
24,
1614
]
],
[
[
1407,
24,
530
],
[
530,
1,
1614
]
],
[
[
1407,
21,
28863
],
[
28863,
60,
1614
]
],
[
[
1407,
63,
999
],
[
999,... | [
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
... | Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Eszopiclone (Compound) causes Lightheadedness (Side Effect) and Lightheadedness (Side Effect) is caused by Nabilone (Compound)
Eszopiclone may cause a moderate i... |
DB00059 | DB00461 | 1,560 | 598 | [
"DDInter1404",
"DDInter1254"
] | Pegaspargase | Nabumetone | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Moderate | 1 | [
[
[
1560,
24,
598
]
],
[
[
1560,
24,
1555
],
[
1555,
63,
598
]
],
[
[
1560,
25,
1259
],
[
1259,
63,
598
]
],
[
[
1560,
24,
1645
],
[
1645,... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabumetone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone
Pegaspargase may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib ma... |
DB00852 | DB06655 | 1,445 | 5 | [
"DDInter1545",
"DDInter1077"
] | Pseudoephedrine | Liraglutide | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
1445,
24,
5
]
],
[
[
1445,
63,
1252
],
[
1252,
23,
5
]
],
[
[
1445,
63,
245
],
[
245,
24,
5
]
],
[
[
1445,
24,
480
],
[
480,
24,... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
... | Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Gl... |
DB01098 | DB13874 | 14 | 1,501 | [
"DDInter1622",
"DDInter639"
] | Rosuvastatin | Enasidenib | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345]. Patients eligible ... | Major | 2 | [
[
[
14,
25,
1501
]
],
[
[
14,
63,
663
],
[
663,
24,
1501
]
],
[
[
14,
24,
1619
],
[
1619,
24,
1501
]
],
[
[
14,
62,
1197
],
[
1197,
... | [
[
[
"Rosuvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enasidenib"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Meth... | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and... |
DB00443 | DB09420 | 251 | 1,074 | [
"DDInter195",
"DDInter953"
] | Betamethasone | Iodide I-123 | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
251,
24,
1074
]
],
[
[
251,
24,
1004
],
[
1004,
63,
1074
]
],
[
[
251,
62,
523
],
[
523,
24,
1074
]
],
[
[
251,
24,
126
],
[
126,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salicylate may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Betamethasone may cause a minor interaction that can limit clinical effects when taken with A... |
DB00382 | DB00782 | 62 | 1,123 | [
"DDInter1734",
"DDInter1535"
] | Tacrine | Propantheline | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Moderate | 1 | [
[
[
62,
24,
1123
]
],
[
[
62,
24,
1192
],
[
1192,
63,
1123
]
],
[
[
62,
24,
1442
],
[
1442,
24,
1123
]
],
[
[
62,
63,
1594
],
[
1594,
... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
],
[
... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.